Abstract Colorectal cancer is a common malignancy and often presents with synchronous or metachronous distant spread. For patients with hepatic metastases, resection is the principal curative option. Liberalization of the indications for hepatic resection has introduced a number of challenges related to the size, distribution, and number of metastases as well as the condition of the future liver remnant. Advances in systemic therapy have solidified its role as both an important adjunct to surgery and also for many patients as a mechanism to facilitate resection. In patients whose disease is marginally resectable as a consequence of the distribution of hepatic lesions that precludes complete resection or out of concern for the future liver remnant, a number of strategies have been advocated, including prehepatectomy systemic therapy, staged surgical approaches, ablative technologies, and preoperative portal vein embolization. It is the purpose of this review to discuss ways in which to optimize the treatment of patients with potentially resectable disease, specifically those who are judged to have "borderline" resectable situations.
In 2014, over 140,000 new patients will be diagnosed with colorectal cancer, and 50,000 patients are expected to die as a result of colorectal cancer [1] . Most colorectal cancer deaths occur in the context of progressive hepatic metastases. Up to 25 % of patients will present with synchronous metastases at the time of initial diagnosis, and ultimately up to 50 % of patients will develop metastatic disease [2, 3] . About one third of patients with hepatic metastases will have disease clinically limited to the liver, whereas the remainder will either present with or develop extrahepatic disease. In the current era, resection is fundamental to the prospects of long-term survival, and as such the critical question in all patients revolves around whether their disease is resectable or potentially resectable. There is a great body of literature describing various risk factors for poor outcomes following partial hepatectomy, and from these a number of groups have advanced recommendations regarding the definition of "resectable." Contemporary thoughts as to what constitutes "resectable" have been addressed within consensus conferences and are best summed up as follows: (1) appropriate medical candidate for surgery, (2) an anticipated R0 resection irrespective of size and multiplicity, and (3) the ability to retain a sufficient liver remnant [4, 5] . The presence of limited extrahepatic disease that is amenable to resection is a relative contraindication. As practiced, this "definition" serves as a guide as some ambiguity arises in defining who is an acceptable medical candidate and also as a result of differing degrees of expertise on the part of individual surgeons. Although the magnitude of the benefit of systemic therapy in patients whose disease has been resected remains controversial, the benefit of contemporary regimens demonstrated in large randomized trials of patients whose disease is not resectable and the markedly improved response rates are such that the patients whose disease is resectable should in general receive systemic therapy in addition to resection. The appropriate sequencing of multimodality therapy in patients whose disease is clearly resectable is somewhat controversial and often nuanced, especially in patients with synchronous presentation. Although there is little to no controversy regarding patients with large burdens of disease that require downsizing to achieve resection, even for these patients nuanced decision making is required in optimizing the timing of surgical therapy while avoiding the problems of disappearing liver metastases (DLM) and unnecessary hepatotoxicity. Given the primacy of surgical resection and these additional considerations, the first aspect of "optimizing" the surgical treatment in patients with "potentially resectable" disease is in ensuring that the patients have been thoughtfully reviewed by a team of providers with expertise. It is vital that the team includes among others an experienced hepatic surgeon, whose involvement is sought early rather than late after the treatment plans have been enacted.
This review focuses on ways in which to optimize the treatment of patients in whom the ability to achieve an R0 resection is in question because of size, multiplicity, and/or location. These patients with "borderline resectable" disease are characterized by a bilateral distribution, high multiplicity, proximity to vascular and biliary structures serving the future liver remnant (FLR), and perceived low FLR volumes. In many of these patients, their disease is truly unresectable, whereas a not insignificant proportion can be converted through a number of innovative strategies to situations where resection is feasible and indicated. Given the dichotomy in outcomes between patients with unresected disease and patients with resected disease, it is critical that almost all medically viable patients with liver-dominant disease are given the benefit of the doubt. Patients whose intrahepatic burden of disease seems unlikely to be resectable should at least have their situations reviewed by a unit with experience in treating patients with very high tumor burdens and in providing the spectrum of options described in the following sections.
Optimizing the Preoperative Assessment of Tumor Burden
Preoperative radiological assessment and staging is key to selecting appropriate candidates for surgical resection of colorectal liver metastases. Bonanni et al. [6•] recently published a series assessing the correlation of CT, MRI, PET/CT, and intraoperative ultrasonography with the final histopathologic findings. They concluded that intraoperative ultrasonography was the most sensitive test for detection of colorectal liver metastasis, and 7.5 % of the time it changed the intraoperative surgical strategies. Although CT is still the gold standard for follow-up, it must be emphasized that in the series of Bonanni et al., CT had the lowest kappa value of concordance with histologically proven liver metastasis, followed by MRI, PET/ CT, and intraoperative ultrasonography. In a systematic review and cost-effectiveness analysis supported by the National Institutes of Health, Westwood et al. [7] compared contrast-enhanced ultrasonography using SonoVue with contrast-enhanced CT and contrast-enhanced MRI for the characterization of focal liver lesions and the detection of liver metastases. They were not able to find consistent evidence of a difference in test performance between the imaging modalities for detection of liver metastases, but contrast-enhanced ultrasonography might be sufficient for ruling out liver metastases in colorectal cancer patients. From a cost-effectiveness standpoint, contrast-enhanced ultrasonography is as cost-effective as contrast-enhanced CT. Niekel et al.
[8] performed a metaanalysis from 1990 to 2010 comparing CT, MRI, and PET to assess performance in detecting colorectal liver metastasis. They concluded that MRI performs better than CT, mainly for lesions smaller than 10 mm, whereas fluorodeoxyglucose PET/CT is mainly useful for evaluation of extrahepatic disease. In our experience and according to an expert consensus statement, we prefer MRI for preoperative planning in many patients, especially those who have received recent systemic therapy and/or who have intrinsic liver disease such as nonalcoholic fatty liver disease [5] . However, the familiarity of most liver surgeons with interpreting CT images and the ease of use in displaying images intraoperatively are such that many surgeons continue to favor CT.
Optimization Through Prehepatectomy Systemic Therapy
Preoperative chemotherapy is administered in either of two strategic settings: neoadjuvant chemotherapy is given preoperatively for initially resectable colorectal liver metastases, whereas conversion chemotherapy is given to patients with initially unresectable patterns of disease in an attempt to render the patient's disease resectable. In the 5-fluorouracil (5-FU) era, response rates were approximately 20 % and in patients with borderline resectable colorectal liver metastases their disease was unlikely to be rendered resectable even in aggressive hepatopancreaticobiliary units. The advent of modern chemotherapeutic agents, however, has led to a greater ability to induce tumor responses and has opened the door for more aggressive treatment of patients with borderline resectable liver metastases. Overall response and 6-month stable disease rates of 50-60 % (Table 1 ) and 90-95 %, respectively, are the expectation with current regimens. A growing number of reported experiences in patients whose disease was resected after conversion therapy suggest excellent outcomes that approach those of patients with initially resectable disease (40-50 % 5-year overall survival). Although they may have high burdens of disease, these salvaged patients are selected by response to therapy, and as such there is an inherent bias toward the inclusion of patients who have more favorable biology. Nonetheless, in the absence of randomized data and given the uniformly poor long-term survival rates of patients with unresected disease even in the era of contemporary chemotherapy, patients whose disease is rendered resectable should, with few exceptions, be offered resection [30] [31] [32] [33] . Although many regimens are used for this approach, the optimal chemotherapy for downsizing tumor burden remains ill defined as there has been no randomized study looking specifically at patients with borderline resectable colorectal liver metastases. In a wellwritten review article, Haraldsdottir et al. [34] summarized the current evidence regarding the optimal systemic treatment for downsizing liver metastases (Table 1) . The current regimens with a high response rate and most often used are leucovorin/5-FU/oxaliplatin (FOLFOX), leucovorin/5-FU/irinotecan (FOLFIRI), and leucovorin/5-FU/ oxaliplatin/irinotecan (FOLFOXIRI), often combined with bevacizumab. Response rates up to 80 % can be achieved with most aggressive approaches [34] . However, it has to be emphasized that the best treatment regimen has not been established and is also highly dependent on the performance status of each individual patient. Further research is definitely warranted.
Proponents of the neoadjuvant approach argue that aside from downsizing tumor burden, preoperative chemotherapy is advantageous in that it allows all patients to receive "necessary" systemic chemotherapy and that postoperative complications after major liver surgery often prohibit timely administration of postoperative systemic therapy. It may also help to select appropriate patients to undergo surgery as it serves as a test of time to identify unfavorable tumor biology where surgery would not be helpful. In addition, the administration of neoadjuvant chemotherapy allows the assessment of tumor response to chemotherapy, and thus may help to guide adjuvant systemic therapy decisions. Proponents have also suggested that the likelihood of an R0 resection is enhanced with the administration of neoadjuvant therapy. The administration of neoadjuvant therapy does present potential disadvantages though, specifically that of increasing the perioperative complications associated with partial hepatectomy and the FOLFIRI leucovorin/5-fluorouracil/irinotecan, FOLFOX leucovorin/5-fluorouracil/oxaliplatin, FOLFOXIRI leucovorin/5-fluorouracil/oxaliplatin/ irinotecan, 5-FU 5-fluorouracil possibility of rendering small but persistent lesions clinically undetectable (disappearing liver lesions). In the EORTC 40983 Intergroup trial of perioperative FOLFOX4, the severe morbidity rate was significantly increased and was a consequence predominantly of tissue-healing-related issues such as bile leak [34] . In the design of this trial, patients were required to undergo hepatectomy within 2-5 weeks after completion of the preoperative therapy, and it is likely that a slightly longer time interval would ameliorate this specific issue. A recently published retrospective analysis of the Memorial SloanKettering Cancer Center from 2003 to 2007 assessed the impact of preoperative chemotherapy on the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer [35•] . In contrast to the EORTC 40983 trial, chemotherapy was stopped much earlier, with a median of 8 weeks prior to liver resection. Very beneficial results were found in regard of preoperative chemotherapy without increased sinusoidal dilatation, steatosis, or steatohepatitis in comparison with patients who had not received preoperative chemotherapy. No difference was found overall when comparing patients who had received preoperative chemotherapy versus patients who had not in regard of postoperative complications or mortality. Major postoperative complications, however, were associated with major liver resections (three or more segments) and perioperative blood transfusions. Although the effectiveness of modern chemotherapy has increased the number of patients who are ultimately candidates for curative resection, dramatic responses to chemotherapy can result in challenging clinical scenarios. Approximately 5-25 % of patients will have complete radiographic response of their colorectal liver metastases [36] [37] [38] [39] . Although such disappearing liver metastases (DLM) can signify favorable biology, they should not be treated as equivalent to pathologic complete responses as this is often not the case on final pathologic examination or intermediate interval follow-up. In fact, residual macroscopic disease can be found during surgery in 25-45 % of DLM, and 25-45 % of the lesions still have viable tumor when examined by microscopy [40] . Complete microscopic response has been reported to occur in 15-70 % of DLM [36, 39, 40] . It has been shown that leaving disappearing liver lesions in situ leads to increased risk of local recurrence, with a median recurrence time of 6-8 months [38, 39] , but its impact on overall survival is much less clear [39] . Currently, we advocate that liver resection should follow initial tumor distribution in the liver whenever feasible [40] . Whether or not stereotactic navigation technology will help to identify disappeared liver lesions and their precise treatment has to be shown [41, 42] . Although hepatocellular-specific contrast-enhanced MRI is currently the gold standard for identification of even small liver lesions, contrast-enhanced intraoperative ultrasonography might soon be a valuable and important alternative [43] . In comparison with conventional intraoperative ultrasonography, contrastenhanced intraoperative ultrasonography has recently been shown to improve the detection rate by about four times [43] . Given these considerations, operative planning in patients with DLM should, in general, encompass all previously known sites of disease unless doing so dramatically increases the expected morbidity or is technically not feasible. There are also reports suggesting that postoperative chemotherapy may be more effective, and as such preoperative regimens are far from mandatory [44] .
In addition to these considerations, it has also been suggested that in the current era of effective systemic therapy, patients with R1 resections have outcomes that are not vastly different from those of patients with R0 resections after 5 years (57 % vs 61 %) [45] [46] [47] . These data remain preliminary and controversial such that attempts to achieve an R0 resection should remain the ideal; nonetheless, they do cast doubt on subjecting patients to prolonged and multiple regimens if the only intent is to better secure a negative margin.
Optimizing the Future Liver Remnant
The principal determinant of outcomes following hepatectomy relates to the quality of the FLR, which is in itself predicted to be of concern by the presence of intrinsic liver disease, the occurrence of intraoperative events, and operative planning that fails to ensure a sufficient future remnant volume with intact support structures. As a general rule, 25-30 % of liver volume must remain after surgical resection in patients without intrinsic liver disease, whereas in patients with underlying liver disease, 30-40 % of liver parenchyma should be preserved [48] . Patients in whom these criteria are exceeded are at excessive risk of postoperative liver failure (PLF). PLF is a major cause of posthepatectomy morbidity, particularly after right hepatectomy and extended hepatectomies [49••] . The International Study Group of Liver Surgery established a simple and easily applicable definition of PLF based on its impact on clinical management [49••] . Whereas grade A PLF does not require any change in clinical management, grade B leads to a deviation from the regular course without requiring invasive therapy, and if invasive treatment is necessary, it is classified as grade C. In a multicenter study on 1,059 patients from the USA, Mullen et al. [50] used the peak bilirubin level and the international normalized ratio to predict postoperative hepatic insufficiency with high sensitivity (93.3 %, 76.7 %, respectively) and high specificity (94.3 %, 82.0 %, respectively).
In addition to careful operative planning, a number of strategies have been introduced in an effort to ensure the presence of an adequate FLR. The increased frequency of complex liver surgery and the use of systemic therapy prior to surgery with its potential associated liver injury are making this topic more and more important. Most established among these is portal vein embolization (PVE). As long ago as 1920, it was shown that portal vein ligation leads to atrophy of the ligated liver lobe with associated hypertrophy of the other side in rabbit experiments [51] . After further animal research, portal vein ligation was first successfully applied in humans with unresectable liver cancer as a palliative procedure in 1975 [52] . Transhepatic PVE was then developed in patients with hepatocellular carcinoma prior to surgical resection because of the fear of tumor-related thrombi in the portal vein system but also to increase the size of the FLR [53] . Over the last 30 years, the technique of PVE significantly evolved, with very high technical success rates of 98.9 %, mean intervention associated morbidity of 3 %, and median in-hospital stays of about 2 days [54] . In the same review article, the mean volume increase of the FLR after PVE is reported to be almost 40 % with a mean time to extended liver resection of about 37 days and a successful resection rate of almost 80 %. Surgically performed portal vein ligation is an alternative to PVE. However, it is associated with a higher procedure-associated morbidity rate of 6 % and a longer hospital stay of about 10 days [54] . Despite a higher hypertrophy rate of the FLR of 65 %, the liver resection rate of 64 % is lower and the time to liver resection is longer. The need for dissection of the hepatoduodenal ligament in the liver hilum to facilitate portal vein ligation is additionally associated with postoperative changes that have the potential to significantly complicate complex liver surgery. Given the dual blood supply to the liver, hepatic arterial embolization was also considered to be an alternative to PVE. It has been shown that hypertrophy of the nonembolized liver lobe can be achieved as well [55] . However, in a recent prospective randomized study from Germany, a direct comparison of hepatic arterial embolization versus PVE in patients with hilar cholangiocarcinoma undergoing extended right hemihepatectomy was highly favorable for PVE because of the increased FLR volume of the left lateral segment [56] . Similar favorable results for PVE were found in a multicenter matched-pair analysis comparing radioembolization of segments of the hepatic artery using yttrium-90 resin microspheres with PVE [57•] . From our perspective, there is currently no justification for portal vein ligation or hepatic arterial (radio)embolization if PVE is technically feasible.
Selection of patients who are the best candidates for PVE is still difficult. Despite the low procedural risk of PVE, liver resection is significantly delayed and the size increase of known tumors or stimulation of micrometastasis in a regenerative milieu especially in the nonembolized segments is observed and feared [58] [59] [60] . In a review of prospectively collected data from the Memorial-Sloan Kettering Cancer Center, patients were further stratified on the basis of whether they received chemotherapy between PVE and surgical resection [61••] . In patients who did not receive chemotherapy after PVE, tumor progression was found in 34 % of the patients during the month after PVE, with an overall mean increase of 8 % in size, independent of whether the lesion was on the embolized side or the contralateral side after PVE. In contrast, patients receiving chemotherapy after PVE had a 13 % decrease in size. No difference was found between the two groups regarding mean growth of the FLR, whereas the complication rate in the no-chemotherapy group after liver resection was slightly higher. Patients undergoing chemotherapy after PVE had an almost twofold increase in 5-year survival compared with their counterparts (49 % vs 24 %, respectively). The same group had already previously shown that liver growth after PVE is independent of whether patients are undergoing neoadjuvant or conversion chemotherapy, a finding confirmed by others [58, 62] . These results suggest that continuation or initiation of peri-PVE chemotherapy could overcome the fear of tumor growth during the waiting period, but additional conformational research is definitely warranted.
However, despite these beneficial findings, it remains controversial whether chemotherapy interferes with the response of the FLR to PVE. Although evidence is leaning toward the view that chemotherapy does not influence hypertrophy response, this might not be generalizable, as the available data are still limited and heterogeneous [63] . Zorzi et al. [64] assessed whether the use of chemotherapy, in general, and bevacizumab,(a vascular endothelial growth factor antagonist), in particular, affected liver regeneration and postoperative morbidity and mortality after PVE in patients with colorectal liver metastasis. On the basis of 65 consecutive patients from 1995 to 2007, they did not find any difference for either comparison. However, others found that patients undergoing peri-interventional standard chemotherapy with bevacizumab showed smaller increases in FLRs compared with patients receiving standard chemotherapy only [65] . It has to be emphasized that one third of the patients in this study underwent portal vein ligation rather than PVE, and that an increasing number of bevacizumab cycles (mean of 12 in this study) was associated with reduced liver growth after portal vein occlusion. Others limited chemotherapy use prior to surgery to five to nine cycles only, with more favorable results [64, 65] . Despite the emerging evidence that limited bevacizumab use does not seem to be interfering with the amount of FLR increase, bevacizumab needs some special surgical attention [58] . Given that vascular endothelial growth factor plays a crucial role in tumor angiogenesis but also in healing injured tissue, it is recommended that bevacizumab use is discontinued about 6 weeks prior to liver resection, whereas normally, standard chemotherapy is stopped at least 4 weeks prior. An additional consideration is that beside direct antitumor activity, bevacizumab seems to have a protective effect against sinusoidal injuries when oxaliplatin-based chemotherapy regimens are used [66] .
Another group of patients who need special attention are patients with impaired liver function prior to PVE. Most of the literature regarding these patients is based on patients with hepatocellular carcinoma, given that chronic hepatitis B, hepatitis C, and alcoholic liver fibrosis are risk factors for both impaired liver function and the development of hepatocellular carcinoma and are much less associated with metastatic colorectal cancer. Patients with Child-Pugh stage B or stage C disease are a priori not considered to be candidates for major liver resection as their risk of developing PLF outweighs its potential benefit. In contrast, the decision is more complicated in patients with Child-Pugh stage A disease. Very often, the underlying chronic liver disease is associated with fibrosis or cirrhosis, with an increase in portal venous pressure and limited functional reserve of the FLR. The latter makes these patients theoretically excellent candidates for preoperative PVE to increase the volume of the FLR while at the same time special considerations have to be respected. Patients with Child-Pugh stage A disease can be stratified further on the basis of functional reserve using the indocyanine green (ICG) tolerance test. Patients with an ICG retention rate after 15 min (ICG-R15) of more than 20 % are currently also not considered candidates for major surgery, whereas it is thought that patients with ICG-R15 of less than 10 % must have an FLR of more than 40 % and those with ICG-R15 of 10-20 % must have an FLR of more than 50 % [67] [68] [69] . Beside the actual value and size of the FLR, it is also important that the FLR has the capacity to undergo hypertrophy [70] . Given the often limited hypertrophy of the FLR, PVE in patients with impaired liver function is more challenging and sometimes needs different and combination approaches to optimize FLR regeneration [71, 72] . This includes extending PVE to segment IV branches, use of small spherical particles over larger, nonspherical particles, additionally to PVE embolization of the ipsilateral hepatic vein, or performing associated liver partition and portal vein ligation for staged hepatectomy [73] [74] [75] [76] . We cannot emphasize enough that especially in those patients, multidisciplinary evaluation of the patient should be performed to decide on preoperative optimization of the liver and to find the optimal timing for surgical resection. If so, major liver resection after PVE can be performed safely even in patients with impaired liver function [77] . Further investigations have to be performed to better standardize PVE and its potential adjuncts in patients with impaired liver function so that postoperative hepatic insufficiency and complications can be minimized even further.
Although the measurement of the standardized FLR as radiographic volume change after PVE is widely accepted to predict PLF and death after liver resection, it has recently been shown that the kinetic growth rate of the FLR is a better measure to predict postoperative hepatic insufficiency in patients undergoing liver resection for colorectal metastasis [78•] . Shindoh et al. [78•] showed that a threshold for the kinetic growth rate of 2.0 % per week to predict postoperative liver insufficiency has a very high accuracy (81 %), with a sensitivity of 100 % and a specificity of 71 %. In comparison, the accuracy using a threshold of standardized FLR of less than 30 % was only 58 % (sensitivity 88 %, specificity 56 %). We strongly believe that this more dynamic measure will be used more frequently in patients where the FLR has a borderline size and the decision about surgery or no surgery is critical.
That PVE is a very important adjunct in centers with a high volume of liver resection is shown in a recent report from the MD Anderson Cancer Center [79] . Of 139 patients who were considered to have inadequate standardized FLR who underwent PVE, 87 (63 %) finally underwent potentially curative extended hepatic resection and were compared wit similar patients without previous PVE. Short-term and longterm outcomes were the same in both groups. However, patients who underwent PVE and resection had significantly better overall survival (50.2 months) compared with patients who were not eligible for resection despite PVE having been performed (24.7 months).
In sum, in experienced hands, PVE is now clearly a standard technique to increase eligibility and safety for patients with borderline resectable colorectal liver metastases, allowing potentially curative resection.
For patients with bilateral disease that is technically resectable except for consideration of the volume of the FLR (i.e., the appropriate support structures can be retained), an alternative approach is to perform bilateral resection in a staged manner. This is most commonly encountered in patients who require a right hepatectomy or an extended right hepatectomy and who also have a small lesion(s) in the left lateral section of the liver amenable to wedge resections. In this strategy, the first stage focuses on clearing the FLR (left lateral section) so that postoperative PVE can be used to augment FLR volume without the theoretical risk of tumor growth in the nonembolized liver. Some surgeons have advocated surgical portal vein ligation instead of postoperative embolization. As clearance of the left lateral section in these patients typically does not require dissection in the duodenal hepatic ligament/ hilum, we do not favor portal vein ligation, which has the potential to create inflammation and adhesions in an area where subsequent dissection will be occurring during the right hepatectomy. In the second stage, resection of the remaining disease is completed after FLR hyperplasia is induced by PVE [80•]. Lam et al. [82] summarized the findings of ten observational studies including a total of 459 patients who presented with initially unresectable colorectal liver metastases. Of those patients intended to undergo two-stage hepatectomy, 352 (77 %) actually underwent also the second stage of the two-stage procedure, with an R0 resection rate of 75 %. Patients who underwent the complete two-stage procedure had a median overall survival of 37 months (range, 24-44 months), whereas patients who underwent only the first stage of surgery had a median survival of 16 months (range, 10-29 months). The 3-year disease-free survival rate was 20 %. Periprocedural mortality was lower than 4 %. In sum, twostage hepatectomy for initially unresectable colorectal liver metastases is safe and effective, and future research needs to establish selection criteria and better define periprocedural therapy [83] .
In an effort to improve on the hypertrophic effects of PVE, recent reports have introduced and described experiences with an alternative two-stage strategy denoted "associating liver partition and portal vein ligation for staged hepatectomy" (ALPPS). In this approach, in situ liver partitioning (parenchymal transection) is performed in conjunction with portal vein ligation on the side that will be resected during the second procedure preserving its hepatic artery, biliary outflow, and hepatic vein. This portion of the liver is typically completely mobilized and a bag is placed around it to prevent adhesions and possibly to collect bile leaks for a short time. The second stage involves ligation of the preserved hepatic vein, hepatic artery, and biliary outflow to the "resected" side and is typically completed within 7-14 days after the FLR has increased in volume. The aim of ALPPS is to create more dramatic and rapid liver hyperplasia through disruption of intrahepatic portal vein collaterals and portal vein ligation compared with the well-established portal vein ligation only. Since its first performance in 2007 in Regensburg by Schlitt et al., ALPPS has been gaining broader interest around the world. Success rates related to R0 resections are high, but postoperative complications and mortality are significant. Nadalin et al. [84• ] reported a mortality rate of 29 % in patients undergoing ALPPS for various reasons, including patients with colorectal liver metastases. This new approach led to great debates about the technique. A temporary comparison of results from the MD Anderson Cancer Center on the efficacy of aggressive PVE including selective embolization of segment IV branches seems to compare favorably with results published for ALPPS [85] . Severe concerns about the safety and effectiveness of ALPPS form the principal objections to this strategy. It is intuitive to consider that early reoperation (i.e., the second stage) would lead to prolonged hospital stays and significant morbidity. Another concern is that unchecked enthusiasm for ALPPS may lead to its overuse in patients who would otherwise have likely done well with either PVE or ALPPS.
Surgical Adjuncts to Clear the Liver of Disease
Adjuncts or alternatives to surgical resection of colorectal liver metastases are finding increasing acceptance. Especially in patients with borderline resectable disease and in patients who are marginal surgical candidates, these alternatives play an important role and can significantly improve overall survival and quality of life [86•, 87] .
Radiofrequency ablation (RFA) is the most commonly used ablative therapy to treat colorectal liver metastases, although other modalities, including microwave ablation and electroporation, are increasing in popularity as well [88] . RFA can be applied during open surgery, during laparoscopy, or percutaneously either in conjunction with other treatments or alone, and is normally well tolerated. RFA can be used to clear the potential FLR of disease with preservation of inflow, outflow, and the biliary duct system even at the same time when PVE is performed [89] [90] [91] . It has been shown that multipolar RFA can even be safely used close to major hepatic vessels without impairment of local tumor progression [92] .
Earlier reports directly compared RFA with liver resection in patients with solitary liver metastasis. Oshowo et al. [93] reported their experience among patients with solitary colorectal liver metastases in 2003. RFA rather than resection was performed in the patient cohort because of proximity to major vessels, comorbidities, or stable extrahepatic disease. Comparisons of 3-year survival rates (53 % vs 55 %, respectively) did not show any meaningful difference. Others found that 4-year survival rates after RFA with (36 %) or without (22 %) concomitant resection were inferior to that after resection alone (65 %) [94] . In addition, higher local recurrence rates and shorter recurrence-free survival were found for patients who underwent RFA. Despite the conclusion of Abdalla et al. [94] that RFA cannot be considered equivalent to hepatic resection, it remains unclear how much of this difference is attributable to selection bias and how much is really ascribable to RFA inferiority. Otto et al. [95] compared first-line RFA with surgical resection in patients with limited colorectal metastatic burden in the liver. The rate of local recurrence was found to be significantly higher in RFA patients (32 % vs 4 % after resection), whereas no difference was found for the rate of systemic recurrence (32 % vs 37 %, respectively). In addition, the time to progression was shorter after RFA (203 days vs 416 days, respectively), and overall survival was the same for both groups. The significantly higher local recurrence rates when using RFA rather than surgical resection with more equal long-term survival rates is confirmed by others and range from 18 to 37 % [96] [97] [98] [99] .
Given that most patients undergo multimodality treatment including different systemic therapy regimens, surgical resection at a later time point, or repeated RFA for local recurrence, it has to be highlighted that it is difficult to assess overall survival on the basis of initial treatment only. In addition, despite many studies trying to have equalized baseline patient characteristics, most studies include patients in the RFA group that would not be surgical candidates for various reasons, always to the disadvantage of the RFA group. As no contemporary randomized controlled trial data exist, it remains somewhat hypothetical what the specific role of RFA should be in the treatment of patients with colorectal liver metastasis. Evidence is emerging from the literature that aside from the treatment of nonsurgical candidates, for patients with higherrisk profiles and where complex liver surgery would be necessary for R0 resection with limited tumor burden deep in the liver, RFA could be a competitive alternative. However, close radiological follow-up is critical given the higher risk of local recurrence. Whether or not clinical equipoise can still be reached to design a prospective randomized controlled trial is questionable but definitely would help to change the perception of believers and nonbelievers of evidence-based decision making.
In addition to ablative modalities, hepatic arterial infusion pump chemotherapy has also been proposed as a means of increasing response and thus resectability in patients with extensive disease burdens. The rationale behind intra-arterial chemotherapy infusion is that liver metastases are mainly vascularized through the hepatic arterial system and that chemotherapy can be administered locally in higher concentrations with increased intrametastatic chemotherapeutic doses and decreased systemic toxicity owing to a high first-pass liver extraction. An expert consensus statement recently summarized the current evidence regarding hepatic arterial infusion [100••] . Among other current questions, some have advocated using contemporary agents within the hepatic arterial infusion regimen. With use of oxaliplatin as a hepatic arterial infusion chemotherapeutic agent together with systemic 5-FU and leucovorin, overall response rates of 64 % when given as first-line treatment and 62 % in salvage situations can be achieved [101, 102] . Kemeny et al. [103] showed that downstaging from initially unresectable disease to a resectable situation can be expected in 47 % of patients, and this proportion reached 57 % in chemotherapy-naïve patients. Others, however, found a conversion rate from unresectable to resectable situations of only 26 % [104] . Importantly, if conversion was successful, a favorable 5-year survival rate of 56 % was attained compared with 0 % for nonsurgical patients. In addition, despite the feared hepatotoxicity of the intraarterial chemotherapy administration, postoperative morbidity and mortality are very comparable with those in patients without prior intra-arterial chemotherapy [33, [104] [105] [106] .
Even with these approaches, there remain patients whose intrahepatic tumor burdens are too extensive to allow resection. Hagness et al. [107, 108•] recently reported the experience of a prospective pilot study on patients with unresectable colorectal liver metastases who underwent liver transplantation because of their disease. Given that chemotherapy would be the only treatment option in patients with extensive liveronly disease, the overall 5-year survival rate of 60 % is extremely favorable and exceeds by far the reported outcome for chemotherapy in this patient population. There has been a significant improvement in overall survival over the last 20 years as reports from the 1990s report 5-year overall survival rates of only 18 % [109] . Martins et al. [110] have addressed the important issue of ethical considerations in this topic given the scarcity of liver organs currently available. Although we also strongly believe that the time has not arrived yet for broad application of this treatment strategy, we emphasize that better selection criteria, further improvements in immunosuppression, and systemic colorectal cancer treatment might justify increased use of this strategy as an additional treatment alternative. Whether or not it will find a way to patients with borderline resectable disease in whom conversion chemotherapy fails has to be shown. Again, further investigations on this topic are needed to confirm the excellent results of Hagness et al. and to elaborate its indication. Until now, this approach has to be named experimental at best.
Simultaneous Resection of Primary Tumor with Liver Metastases
A final consideration lies in the appropriate sequencing of surgical therapies in patients with synchronous presentations.
A number of groups have demonstrated the feasibility and appropriateness of concomitant primary and metastatic resections, especially in those patients requiring lower-complexity procedures [111] [112] [113] . There are a number of considerations that preclude concomitant resections, including the complexity of procedures, incisional considerations, and body habitus, such that for many patients this approach is not appropriate. When staged procedures are necessary, one must construct strategies that ensure the highest likelihood of resectability. Although the traditional paradigm is to proceed with resection of the primary tumor first, extensive data exist showing that primary tumors respond well to neoadjuvant systemic therapy and uncommonly lead to complications when resection is delayed. As such, for patients who require downsizing to achieve resection of their hepatic metastases, the primary tumor should be prioritized after resection of the metastatic tumor burden. The rationale behind the liver-first approach is mainly to improve the chance of clearing the liver of metastatic disease, acknowledging that this often will dictate longterm outcome in those patients [114] . Insufficient data currently exist to draw any final conclusion about long-term outcomes, as the tumor burden of patients undergoing the liver-first approach was most often higher than in their comparator groups [115] [116] [117] .
Conclusion
Contrary to the notion that hepatectomy and systemic therapies are competing therapies, it is clear that further improvements in systemic therapy will continue to expand the role of aggressive surgical therapy. The current era of more effective systemic therapy and novel strategies to address inadequate FLRs has greatly improved the outlook of patients with significant hepatic tumor burdens. Although one-stage open surgical resection is still optimal when technically feasible, treatment alternatives, including two-stage surgery, ALPPS, thermal ablation, hepatic arterial infusion pumps, and perhaps liver transplantation, have specific roles in these patients. An appreciation of these considerations is critical and required of medical and surgical oncologists who treat these patients. 9. Tournigand C, Andre T, Achille E, et al. 
